Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis
- 378 Downloads
Ovarian neoplasms secondary to germline BRCA mutations had been described to have a more favourable survival. There is only few data concerning the prognosis of non mutated patients presenting clinical features evocative of BRCA alterations. We retrospectively collected data from patients treated in our institution for an invasive ovarian carcinoma between 1995 and 2011. Patients considered at high risk of BRCA mutation were tested for BRCA1/2 germline mutations. We described clinical, pathological and therapeutic features and compared prognosis of BRCA mutation carriers and non-mutated patients. Out of 617 ovarian cancer patients, we identified 104 patients who were considered at high risk of mutation. The 33 mutated patients were more likely to present a personal (33 vs. 10 %, p = 0.003) or a family (42 vs. 24 %, p = 0.06) history of breast/ovarian cancers. BRCA1/2 mutation carriers and wild type patients displayed similar prognosis: median progression–free survival (PFS) of 20.9 versus 37.7 months (p = 0.21); median overall survival (OS) of 151.2 versus 122.5 months (p = 0.52). Personal history of breast cancer increased both PFS [HR = 0.45 (95CI 0.25–0.81)] and OS [HR = 0.35 (95CI 0.16–0.75)]. In multivariate analysis, this parameter was an independent prognostic feature, whereas the identification of a BRCA1/2 mutation was not. In our cohort, all patients at high risk of BRCA mutation share a similar prognosis, whatever is their germline mutation status. Prognosis seems to be more influenced by clinical history than by germline mutations identification. If it is confirmed in larger and independent series, this result suggests that the hypothesis of other BRCA pathway alterations (BRCAness phenotype) deserves to be deeply explored.
KeywordsOvarian cancer BRCA Mutation Prognosis
Compliance with ethical standards
Conflict of interest
The authors have no conflict of interest to declare.
- 1.Binder-Foucard F, Belot A, Delafosse P, et al. (2013) Estimation nationale de l’incidence et de la mortalité par cancer en France entre 1980 et 2012. Partie 1—Tumeurs solides. Institut de veille sanitaireGoogle Scholar
- 10.Tan DSP, Rothermundt C, Thomas K et al (2008) “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26:5530–5536. doi: 10.1200/JCO.2008.16.1703 CrossRefPubMedGoogle Scholar
- 15.Alsop K, Fereday S, Meldrum C et al (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30:2654–2663. doi: 10.1200/JCO.2011.39.8545 CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Konstantinopoulos PA, Spentzos D, Karlan BY et al (2010) Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 28:3555–3561. doi: 10.1200/JCO.2009.27.5719 CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol 21:3194–3200. doi: 10.1200/JCO.2003.02.153 CrossRefPubMedGoogle Scholar
- 47.Bilici A, Salepci T, Dane F et al (2010) Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience. Arch Gynecol Obstet 282:417–425. doi: 10.1007/s00404-009-1330-7 CrossRefPubMedGoogle Scholar
- 65.van Houwelingen JC, ten Bokkel Huinink WW, van der Burg ME et al (1989) Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol Off J Am Soc Clin Oncol 7:769–773Google Scholar
- 67.Ledermann J, Harter P, Gourley C et al (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15:852–861. doi: 10.1016/S1470-2045(14)70228-1 CrossRefPubMedGoogle Scholar